抗拉沙病毒药物的研究进展
Recent progress in the development of inhibitors of the Lassa virus
刘贞麟 1李志豪 1刘奇 1王聪1
作者信息
- 1. 大理大学基础医学院病原生物学综合实验室,大理 671000
- 折叠
摘要
拉沙病毒(LASV)属于沙粒病毒科,哺乳动物病毒属.拉沙病毒可引起严重的急性出血热疾病,即拉沙热.拉沙热总病死率为1％,住院患者的病死率为15％.拉沙热主要在西非流行.目前,尚无FDA批准的针对LASV的特异性药物及疫苗,治疗策略仅限于在疾病早期给予利巴韦林,近年来报道的一些新型抗拉沙病毒药物已经进入临床研究阶段.根据美国疾病预防控制中心的报道,LASV被认为是A类病原体,它的高死亡率和治疗的局限性,世界卫生组织已经将拉沙热确定为研究和开发特效疫苗和药物的重中之重.本文将对拉沙病毒抑制剂的研究进展进行综述.
Abstract
Lassa virus(LASV),a member of Arenaviridae family,is the cause of severe acute hemorrhagic fever,known as Lassa fever,which has an overall fatality rate of 1％,but up to 15％in hospitalized patients.LASV is mainly endemic in West Africa.At present,there is no approved drug or vaccine for LASV,and treatment is limited to ribavirin in the early dis-ease stage.Although some drugs have entered the clinical stage,most have been studied in cellular and animal models.Accord-ing to the Centers for Disease Control and Prevention,LASV is a Class A pathogen due to a high mortality rate and limited treatment options.The World Health Organization has identified Lassa fever as a top priority for research and development.This article reviews recent progress in the development of LASV inhibitors.
关键词
拉沙病毒/抑制剂/包膜糖蛋白复合物/病毒靶标Key words
Lassa virus/inhibitor/envelope glycoprotein complex/virus targe引用本文复制引用
基金项目
国家自然科学基金项目(82360727)
云南省地方高校联合专项-面上项目(202101BA070001-114)
出版年
2024
国家科技期刊平台
NSTL
万方数据